Baxano Surgical CEO Acquires $3,800 in Stock (BAXS)
Baxano Surgical (NASDAQ:BAXS) CEO Kenneth Michael Reali purchased 10,000 shares of the company’s stock on the open market in a transaction that occurred on Friday, August 15th. The shares were purchased at an average cost of $0.38 per share, for a total transaction of $3,800.00. Following the completion of the transaction, the chief executive officer now directly owns 141,128 shares of the company’s stock, valued at approximately $53,629. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Baxano Surgical (NASDAQ:BAXS) traded up 5.77% during mid-day trading on Tuesday, hitting $0.3903. The stock had a trading volume of 309,695 shares. Baxano Surgical has a 52 week low of $0.36 and a 52 week high of $1.99. The stock’s 50-day moving average is $0.50 and its 200-day moving average is $0.86. The company’s market cap is $18.9 million.
Baxano Surgical (NASDAQ:BAXS) last posted its quarterly earnings results on Tuesday, August 5th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by $0.04. On average, analysts predict that Baxano Surgical will post $-0.58 earnings per share for the current fiscal year.
Baxano Surgical Inc, formerly TranS1 Inc, is a medical device company focused on designing, developing and marketing products that implement its approach to treat degenerative conditions of the spine affecting the lower lumbar region.
Receive News & Ratings for Baxano Surgical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxano Surgical Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.